

### **COMPANY OVERVIEW**

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.

## **RECENT NEWS**

Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results Mar 22 2024, 8:00 AM EDT

Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform Jan 17 2024, 9:00 AM EST

**STOCK OVERVIEW** 

Symbol	XBIO
Exchange	Nasdaq
Market Cap	6.19m
Last Price	\$4.015
52-Week Range	\$2.55 - \$5.97

04/16/2024 03:38 PM EDT

# INVESTOR RELATIONS

JTC Team, LLC. Jenene Thomas T: 833-475-8247 xbio@jtcir.com

#### **MANAGEMENT TEAM**

Jeffrey F. Eisenberg Chief Executive Officer

Curtis Lockshin, Ph.D. Chief Scientific Officer

James F. Parslow Chief Financial Officer

Scott N. Cullison Business Development

**Reid P. Bissonnette, Ph.D.** Translational Research and Development

# **XENETIC BIOSCIENCES, INC.**

945 Concord Street Framingham, MA 01701 US

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.